Stifel Maintains Buy on Syndax Pharmaceuticals, Raises Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Bradley Canino maintains a Buy rating on Syndax Pharmaceuticals (NASDAQ:SNDX) and raises the price target from $40 to $42.
June 26, 2024 | 2:07 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Bradley Canino maintains a Buy rating on Syndax Pharmaceuticals and raises the price target from $40 to $42.
The Buy rating and increased price target from a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100